Hematological Malignancies, Solid Tumors

BTX-1188, our lead product candidate, is a rationally designed dual-targeting molecular glue degrader of GSPT1 and IKZF1/3 that we are developing for the treatment of hematologic malignancies and solid tumors. We believe that the combination of degrading GSPT1, a promising oncology target, and IKZF1/3, clinically validated immunomodulatory targets, provides advantages relative to GSPT1-only degradation. We are currently enrolling patients in a Phase 1/2 clinical trial of BTX-1188 with preliminary results expected in mid-2023.